Viewing Study NCT04690595



Ignite Creation Date: 2024-05-06 @ 3:37 PM
Last Modification Date: 2024-10-26 @ 1:53 PM
Study NCT ID: NCT04690595
Status: RECRUITING
Last Update Posted: 2024-05-10
First Post: 2020-12-24

Brief Title: BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Sponsor: PeproMene Bio Inc
Organization: PeproMene Bio Inc

Study Overview

Official Title: A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Status: RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Detailed Description: This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back recurrent or does not respond to treatment refractory T cells are infection fighting blood cells that can kill cancer cells The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize BAFFR a protein on the surface of cancer cells These BAFFR-specific T cells may help the bodys immune system identify and kill BAFFR cancer cells

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None